Shanghai-based cancer therapy developer LaNova Medicines Ltd announced it has received approval from the U.S. Food and Drug Administration (FDA) to conduct an open-label, multi-center Phase I/II study of LM-305, an antibody drug conjugate (ADC) targeting GPRC5D, in patients with multiple myeloma (MM).
Drug Profile
LM-305 is the first GPRC5D-targeting ADC to advance to clinical trials. GPRC5D, a novel drug target, is highly expressed in malignant bone marrow plasma cells and hair follicles but shows little to no expression in normal tissues. The receptor is specifically upregulated in MM patients in a BCMA-independent manner, positioning it as a key target for MM treatment.
Clinical Trial Details
The Phase I/II study will assess LM-305’s safety, tolerability, pharmacokinetics, and preliminary efficacy in MM patients. The trial marks a significant step in LaNova’s efforts to develop therapies targeting GPRC5D.-Fineline Info & Tech
